Navigation Links
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in 100 countries.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patients Taking Nexavar

Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer

Nexavar may cause fetal harm when administered to a pregnant woman. Women of childbearing potential are advised to avoid becoming pregnant and female patients should also be advised against breastfeeding while receiving Nexavar

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar

Uncommon but serious adverse reactions, including keratoacanthomas/squamous cell cancer of the skin and Stevens-Johnson Syndrome, have been reported in clinical trials

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adve
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
2. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
3. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
4. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
5. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
8. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... , Nov. 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: ... webcasting its corporate presentations at two upcoming investor conferences.  ... London, UK on Tuesday, December 2, 2014 at 6:45 ... vice president and head of EUSA International, will provide an overview ... 26 th Annual Piper Jaffray Healthcare Conference in ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2
... 31 Greenway Medical Technologies, Inc. today announced ... (HIE) programs, Independent Physician Associations (IPA) and regional ... company,s integrated electronic health record (EHR) practice management ... streamline clinical, financial and administrative functions. ...
... Corporation, a spinal and orthopaedic implant and instrument ... technologies, announced today that it has been granted ... improved knee implant prosthesis that features a monoblock ... prosthetic (resurfaced) femoral surfaces.  This is an important ...
Cached Medicine Technology:Greenway Selected by Health Information Exchanges and Regional Physician Groups 2Greenway Selected by Health Information Exchanges and Regional Physician Groups 3Greenway Selected by Health Information Exchanges and Regional Physician Groups 4Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component 2Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component 3
(Date:11/26/2014)... The family foundation of Best Buy founder, Richard ... Foundation (Meso Foundation), half of which will be specifically ... Program . The focus area of the Richard M. ... organizations that can generate transformational results in education, human ... and chairman emeritus of Best Buy Co., Inc., the ...
(Date:11/26/2014)... 2014 Increasing demand for diagnostic ... guided surgeries has paved way for consequent increase ... of various types of cancers and cardiac diseases ... demand for these owing to their use in ... injectors market can also be attributed to advancements ...
(Date:11/26/2014)... The American Anthropological Association (AAA) has ... of meetings and conferences. Suvarnakar will be responsible ... and conferences. , “I am pleased to ... Executive Director Ed Liebow. “She brings the Association ... was recognized in January as the 2013 Professional ...
(Date:11/26/2014)... 2014 Gone are the days when throngs ... Black Friday, which signifies the beginning of the Christmas shopping ... shopping carts in the comfort of their homes or on ... Friday is going to be an occasion with one of ... estimated $2.48 billion in revenue for online retailers according to ...
(Date:11/26/2014)... November 26, 2014 For its ... published The AIS Report on Blue Cross and Blue ... Inc. on the varied strategies the two Blues plans ... compliance with treatments for sleep apnea, ranging from brick-and-mortar ... because it’s linked to increased rates of a variety ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3
... do not achieve statistical significance, - GPC Biotech schedules conference call ... ... ET/13:30 CET, BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON,N.J., ... AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq:,GPCB) today announced topline ...
... Survival Results Do Not Achieve Statistical Significance, ... SPPI ) licensee, GPC Biotech, today,announced that ... the,treatment of hormone-refractory prostate cancer did not meet ... that the overall survival data for,satraplatin did not ...
... Oct. 30 Barr,Pharmaceuticals, Inc. (NYSE: BRL ... has received tentative approval from the U.S. Food ... Boehringer Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) (Pramipexole Dihydrochloride) Tablets,0.125mg, 0.25mg, ... it is the,first to file an Abbreviated New ...
... at the Albert Einstein College of Medicine of Yeshiva ... can be successfully treated by targeting the viruses ... 31 issue of PloS One, also raise the possibility ... turn cancerous. , The Einstein researchers used a technique ...
... 79% Growth Over Prior Year Quarter; ... 2008 Guidance, COEUR D,ALENE, Idaho, Oct. 30 ... provider of radiology,solutions to radiology groups across the United ... September 30, 2007. Revenue,grew 79% year-over-year to a record ...
... and OMX Nordic Exchange: EPCT) today announced that Jack ... BioFin Rodman & Renshaw,9th Annual Healthcare Conference on November ... York Palace Hotel in New York. Mr. Talley will ... The presentation will be available live via webcast ...
Cached Medicine News:Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 2Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 3Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 4Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 2Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 2Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 4Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 2Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Gilson disposable pipette tips, TowerPacks ... version. Each Sterilized TowerPack is ... plastic to help protect tips ... by the red sticker, which ...
... racks of 96 tips, Sterilized Diamond- Tips ... Sterilized Diamond Tips are irradiated by gamma-rays ... with a certificate of sterilization, specifying the ... certified free of detectable Rnase, Dnase, DNA, ...
MBP's extra long 200 L pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
Medicine Products: